本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002287 证券简称：奇正藏药 公告编号：2026-008 一、股东股份质押基本情况 西藏奇正藏药股份有限公司（以下简称"公司"、"本公司"）近日接到控 股股东甘肃奇正实业集团有限公司（以下简称"奇正集团"）函告，获悉奇正集 团所持有本公司的部分股份被质押。奇正集团为公司控股股东，持有公司 364,546,473股，占公司总股本的63.72%。具体事项如下： 2、股东股份累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 单位：股 | 股东 | 持股数量 | 持股 | 本次质押 | 本次质押后 | 占其 | 占公司 | 已质押股份情 | 未质押股份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 比例 | 前质押股 | 质押股份数 | 所持 | 总股本 | 况 | 情况 | 西藏奇正藏药股份有限公司 关于控股股东股份质押的公告 ②以上数据若出现尾差，均由四舍五入原因造成。 二、其他说明 1、本 ...

证券代码：002287 证券简称：奇正藏药 公告编号：2026-007 西藏奇正藏药股份有限公司 关于高级管理人员减持股份的预披露公告 高级管理人员李军先生保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示：持有西藏奇正藏药股份有限公司（以下简称"公司"、"本公司"） 股份 192,945 股（占公司剔除已回购股份后的总股本比例 0.0340%）的高级管理 人员李军先生计划在本公告披露之日起 15 个交易日后的三个月内以集中竞价方 式减持本公司股份不超过 48,200 股（占公司剔除已回购股份后的总股本比例 0.0085%）。 一、股东的基本情况 二、本次减持计划的主要内容 （一）本次减持相关情况 公司近日收到高级管理人员李军先生出具的《股份减持计划告知函》，现将 具体情况公告如下： 1、拟减持原因：个人资金需求。 2、拟减持股份来源：股权激励授予（含前述股份因送股增加的股份）。 截至本公告日，公司高级管理人员李军先生持股情况如下： 3、拟减持股份数量与比例： | 序号 | 股东姓名 | 任职情况 | ...

Core Viewpoint - Qizheng Tibetan Medicine (002287) reported its 2025 performance, showing a revenue of 2.416 billion yuan, representing a year-on-year growth of 3.34%, and a net profit attributable to shareholders of 646 million yuan, reflecting a year-on-year increase of 10.98% [1] Financial Performance - The company achieved an operating income of 2.416 billion yuan in 2025, which is a 3.34% increase compared to the previous year [1] - The net profit attributable to shareholders reached 646 million yuan, marking a 10.98% growth year-on-year [1]

Core Viewpoint - Qizheng Tibetan Medicine reported a revenue of 2.416 billion yuan for the fiscal year 2025, marking a year-on-year growth of 3.34%, with a net profit attributable to shareholders of 646 million yuan, up 10.98% [1] Group 1: Financial Performance - The company achieved a total operating revenue of 2.416 billion yuan, reflecting a growth of 3.34% year-on-year [1] - The net profit attributable to shareholders reached 646 million yuan, representing a year-on-year increase of 10.98% [1] - The net profit after deducting non-recurring gains and losses was 477 million yuan, which is a 12.03% increase compared to the previous year [1] Group 2: Business Operations - Qizheng Tibetan Medicine specializes in the research, production, and sales of Tibetan medicine, including external pain relief medications and oral Tibetan traditional medicines [1] - The growth in net profit for 2025 is primarily attributed to the increase in total operating revenue [1] Group 3: Regulatory Approval - The company's wholly-owned subsidiary in Macau recently obtained a registration certificate for traditional Chinese medicine from the Macau government [1] - The approved product, a classic Tibetan medicine called "Cuitang Granules," is now registered as an over-the-counter (OTC) medicine, allowing it to be sold directly to consumers through local retail pharmacies [1] - The prescription for Cuitang Granules is based on a Tibetan formula documented in the 15th century by renowned Tibetan medicine scholar Suka Nyangni Dorgi, intended for respiratory ailments [1]

Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

Group 1 - The company, Qizheng Tibetan Medicine, announced that it expects to achieve an operating revenue of 2,416.01 million yuan in 2025, representing a year-on-year growth of 3.34% [2] - The net profit attributable to shareholders of the listed company is projected to be 646.23 million yuan, reflecting a year-on-year increase of 10.98% [2]

Group 1 - The core point of the article is that Qizheng Tibetan Medicine reported its total number of shareholders as 32,979 as of February 10, 2026 [2]

Group 1 - The company, Qizheng Tibetan Medicine (002287.SZ), reported a total operating revenue of 2.416 billion yuan for the fiscal year 2025, representing a year-on-year growth of 3.34% [1] - The net profit attributable to shareholders of the listed company reached 646 million yuan, showing a year-on-year increase of 10.98% [1]

Core Viewpoint - Qizheng Tibetan Medicine (002287.SZ) reported its 2025 annual performance, showing a total operating revenue of 2.416 billion yuan, an increase of 3.34% compared to the same period last year, and a net profit attributable to shareholders of the listed company of 646 million yuan, representing a year-on-year growth of 10.98% [1] Financial Performance - The company achieved total operating revenue of 2.416 billion yuan [1] - The year-on-year growth in total operating revenue was 3.34% [1] - The net profit attributable to shareholders reached 646 million yuan [1] - The net profit saw a year-on-year increase of 10.98% [1]

Core Viewpoint - Qizheng Tibetan Medicine (002287.SZ) reported its 2025 annual performance, showing a steady growth in revenue and net profit, indicating a positive trend in the company's financial health [1] Financial Performance - The company achieved a total operating revenue of 2.416 billion yuan, representing a year-on-year increase of 3.34% [1] - The net profit attributable to shareholders of the listed company was 646 million yuan, reflecting a year-on-year growth of 10.98% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 477 million yuan, which is a year-on-year increase of 12.03% [1]